Ingenol mebutate gel for actinic keratosis: The link between quality of life, treatment satisfaction, and clinical outcomes

Journal of the American Academy of Dermatology

Volumn 72, Issue 5, 2015, Pages 816-821

  Augustin, Matthias ^a   Tu, John H ^b,c   Knudsen, Kim Mark ^d   Erntoft, Sandra ^d   Larsson, Thomas ^d   Hanke, C William ^e  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Dermatology Associates of Rochester   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^d LEO PHARMA A S   (Denmark)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

actinic keratosis; clearance; ingenol mebutate; quality of life; Skindex 16; Treatment Satisfaction Questionnaire for Medication

Indexed keywords

INGENOL MEBUTATE; 3-INGENYL ANGELATE; DITERPENE; DRUG VEHICLE; GEL;

ACTINIC KERATOSIS; ADULT; AGE; AGED; ARTICLE; ASSESSMENT OF HUMANS; BOTHERSOMENESS; CONTROLLED STUDY; EMOTION; FEMALE; GEL; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT SATISFACTION QUESTIONNAIRE FOR MEDICATION SCORE; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG SELF ADMINISTRATION; KERATOSIS, ACTINIC; METABOLISM; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; QUESTIONNAIRE; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; DITERPENES; DRUG ADMINISTRATION SCHEDULE; GELS; HUMANS; KERATOSIS, ACTINIC; PATIENT SATISFACTION; PHARMACEUTICAL VEHICLES; QUALITY OF LIFE; QUESTIONNAIRES; SELF ADMINISTRATION; TREATMENT OUTCOME;

EID: 84928297526     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2015.01.036     Document Type: Article

References (28)

1. L.H. Goldberg, and A.J. Mamelak Review of actinic keratosis, part I: etiology, epidemiology and clinical presentation J Drugs Dermatol 9 2010 1125 1132
2. N.A. Fenske, J. Spencer, and F. Adam Actinic keratoses: past, present and future J Drugs Dermatol 9 Suppl 2010 S45 S49
3. D. de Berker, J.M. McGregor, and B.R. Hughes Guidelines for the management of actinic keratoses Br J Dermatol 156 2007 222 230
4. V.D. Criscione, M.A. Weinstock, M.F. Naylor, C. Luque, M.J. Eide, and S.F. Bingham Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs topical tretinoin chemoprevention trial Cancer 115 2009 2523 2530
5. J.L. Cohen Actinic keratosis treatment as a key component of preventive strategies for nonmelanoma skin cancer J Clin Aesthet Dermatol 3 2010 39 44
6. K.E. Sharquie, S.A. Al-Mashhadani, A.A. Noaimi, and A.A. Hasan Topical zinc sulphate (25%) solution: a new therapy for actinic keratosis J Cutan Aesthet Surg 5 2012 53 56
7. M. Vatve, J.P. Ortonne, M.A. Birch-Machin, and G. Gupta Management of field change in actinic keratosis Br J Dermatol 157 Suppl 2007 21 24
8. S. Esmann, and G.B. Jemec Management of actinic keratosis patients: a qualitative study J Dermatolog Treat 18 2007 53 58
9. K.E. Thai, P. Fergin, and M. Freeman et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses Int J Dermatol 43 2004 687 692
10. M.M. Chren, R.J. Lasek, L.M. Quinn, E.N. Mostow, and S.J. Zyzanski Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness J Invest Dermatol 107 1996 707 713
11. C.A. Prinsen, J. de Korte, and M. Augustin et al. Measurement of health-related quality of life in dermatological research and practice: outcome of the EADV taskforce on quality of life J Eur Acad Dermatol Venereol 27 2013 1195 1203
12. A. Pflugfelder, A.K. Welter, and U. Leiter et al. Open label randomized study comparing 3 months vs 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group J Eur Acad Dermatol Venereol 26 2012 48 53
13. M.M. Chren, R.J. Lasek, A.P. Sahay, and L.P. Sands Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases J Cutan Med Surg 5 2001 105 110
14. M.J. Atkinson, A. Sinha, and S.L. Hass et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease Health Qual Life Outcomes 2 2004 12
15. R.H. Rosen, A.K. Gupta, and S.K. Tyring Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response J Am Acad Dermatol 66 2012 486 493
16. LEO Pharma A/S. Picato (ingenol mebutate) gel, 0.015%, 0.05%. Prescribing information. Available from: URL: www.picato.com/-pdf/PrescribingInformation.pdf. Accessed February 13, 2015.
17. LEO Pharma A/S. Picato 150 micrograms/gram gel. Summary of product characteristics. Available from: URL: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002275/WC500135327.pdf. Accessed February 13, 2015.
18. M. Lebwohl, N. Swanson, L.L. Anderson, A. Melgaard, Z. Xu, and B. Berman Ingenol mebutate gel for actinic keratosis N Engl J Med 366 2012 1010 1019
19. G. Martin, and N. Swanson Clinical findings using ingenol mebutate gel to treat actinic keratoses J Am Acad Dermatol 68 Suppl 2013 S39 S48
20. L. Anderson, G.J. Schmieder, and W.P. Werschler et al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis J Am Acad Dermatol 60 2009 934 943
21. M. Lebwohl, S. Shumack, L.S. Gold, A. Melgaard, T. Larsson, and S.K. Tyring Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses JAMA Dermatol 149 2013 666 670
22. D.T. Tran, and R. Salmon Field treatment of facial and scalp actinic keratoses with photodynamic therapy: survey of patient perceptions of treatment satisfaction and outcomes Australas J Dermatol 52 2011 195 201
23. J.S. Rhee, B.A. Matthews, M. Neuburg, M. Burzynski, and A.B. Nattinger Creation of a quality of life instrument for nonmelanoma skin cancer patients Laryngoscope 115 2005 1178 1185
24. M.A. Weinstock, K.C. Lee, M.M. Chren, and K. Marcolivio Quality of life in the actinic neoplasia syndrome: the VA topical tretinoin chemoprevention (VATTC) trial J Am Acad Dermatol 61 2009 207 215
25. K. Lee, and M. Weinstock Prospective quality of life impact of actinic keratoses: observations from the Veterans Affairs topical tretinoin chemoprevention trial Acta Derm Venereol 91 2011 101 102
26. S. Esmann, and G.B. Jemec Patients' perceptions of topical treatments of actinic keratosis J Dermatolog Treat 25 2014 375 379
27. A.K. Gupta, M. Paquet, E. Villanueva, and W. Brintnell Interventions for actinic keratoses Cochrane Database Syst Rev 12 2012 CD004415
28. C.S. Carlin, S.R. Feldman, J.G. Krueger, A. Menter, and G.G. Krueger A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis J Am Acad Dermatol 50 2004 859 866